Imspex Diagnostics was born in 2011 when Imspex Diagnostics Ltd was founded in a South Wales valley following a death in the Imspex family.
It was an avoidable death. This death would not have happened with an earlier diagnosis.
Ours is not a unique story and thankfully this was not where the story ended for us. What is unique is the business that grew out of the experience – a dynamic, determined and entrepreneurial mix of analytical chemistry experts, data science specialists, medical device and healthcare veterans and sound business acumen with a shared goal of developing and distributing an early warning system that saves life, time and money in medical, environmental and industrial matters.
Since then the business has grown, acquired international partners, G.A.S. mbH, a high-tech analytics developer and manufacturer of GC-IMS instruments and solutions, secured international interest in its shareholding and set up Imspex Medical as a dedicated analytical division for medical and healthcare screening and diagnosis.
The Imspex story will continue as our business grows, embraces opportunities and navigates bends in the road. Wherever the road may lead, we remain people with a passion for putting great science to use for the greater good.
Improving outcomes for people remains at the centre of what we do. Our mission is to use our combined chemistry, analytical, healthcare and business skill to create early warning systems that minimise damage and maximise health, wellbeing and economic prosperity.
We see a world where acceptable, accessible and cost-effective early warning systems proactively prevent damage, slow down deterioration and allow people and the planet to be the best that they can be. Responsibility and stewardship are important to us.
For centuries people have wanted to be able to diagnose medical conditions using breath. Until the advent of breath analysis technology, this goal has remained elusive.
Modern analytics technology and computing power has opened this metabolic window on our physiology. Breathomics is now a fast-growing and specialist area of expertise. It is ideally placed to meet the challenge of detecting the presence of disease earlier than we have been able to do up to now.
We know that earlier diagnosis and targeted treatment can make all the difference to health, quality of life and affordability of healthcare, so our immediate remit at Imspex Medical is to make breath analysis more widely accessible to detect chronic and infectious disease states accurately and quickly.
Over the past decade, the Imspex Group has provided a cutting edge analytics service to the industrial and food and drink sectors using a unique combination of gas chromatography (GC) and Ion Mobility Spectrometry (IMS) technologies. More latterly, it became apparent that this GC-IMS platform also quickly and effectively analyses human breath samples to detect physiological indicators of a range of disease states, including non-transferrable chronic lifestyle- and infectious diseases.
New times, new technology
Imspex Medical’s combination of GC-IMS devices and corresponding expertise provides a feasible public health resource in the form of accessible, non-invasive, reliable breath tests and multiple body fluid analyses that rapidly identify stipulated disease states with the accuracy of the gold standard tests.
This combination holds a key to making high-stakes decisions with more confidence – getting back to work, school and university safely, being able to resume sports, leisure and holiday activities and slowing the development of antimicrobial resistance by supporting appropriate prescription of antibiotics are just a few.
Being able to make these decisions with confidence is the future that we are moving to at Imspex Medical.